Optimizing efficiency and safety of targeted gene correction

8
Optimizing efficiency and safety of targeted gene correction Homology-directed repair NHEJ religation in situ Cleave or nick

description

Optimizing efficiency and safety of targeted gene correction. NHEJ. Cleave or nick. religation in situ. Homology-directed repair. 25 20 15 10 5 0. 21-fold. Foci per nucleus. 0.4 21 1. - H2AX foci induced by cleavase but not nickase. Merge/DAPI. - H2AX. -. - PowerPoint PPT Presentation

Transcript of Optimizing efficiency and safety of targeted gene correction

Page 1: Optimizing  efficiency and safety of targeted gene correction

Optimizing efficiency and safety of targeted gene correction

Homology-directed repair

NHEJ religationin situ

Cleave or nick

Page 2: Optimizing  efficiency and safety of targeted gene correction

-

I-AniI Cleavase

I-AniINickase

-H2AX Merge/DAPI

-H2AX: cleavase/nickase

0.4 21 1

25

20

15

10

5

0

Fociper

nucleus

21-fold

-H2AX foci induced by cleavase but not nickase

Page 3: Optimizing  efficiency and safety of targeted gene correction

Reporter:

Cleavage-associatedgenomic instability

Products:

Inversion following cleavage at both sites

Deletion following cleavage at both sites

Processing and NHEJ of a single cleavage event

polyAP

LHE LHE

H2Kd+, CD4-H2-Kd CD4

CD8

P

H2Kd-, CD4+CD4

polyAP

LHE

H2Kd-, CD4-2-Kd CD4

CD8

P

LHE LHE

CD8+, H2Kd-, CD4-

polyA

H2-Kd

CD8 CD4

A non-homologous end joining (NHEJ) reporter

Guirouilh-Barbat et.al. 2004

Page 4: Optimizing  efficiency and safety of targeted gene correction

-

Gene correction and NHEJ:a model for optimization

gfp-

-

NHEJ

-

Page 5: Optimizing  efficiency and safety of targeted gene correction

-

Gene correction and NHEJ:a model for optimization

gfp-

-

NHEJ

-

GFP

donor templateLHE

transfect

Page 6: Optimizing  efficiency and safety of targeted gene correction

-GFP+

-

NHEJ

-x

Gene correction and NHEJ:a model for optimization

Page 7: Optimizing  efficiency and safety of targeted gene correction

100 101 102 103 104

100

101

102

103

104

100 101 102 103 104

100

101

102

103

104

100 101 102 103 104

100

101

102

103

104

2.4% 14.5%

0.23% 0.11%

0.37%

97.3% 84.4%

0.42%

0.29% 0.003%

0.004%

H2-Kd (PE)

GFP

Cell line Targeting (%) H2-Kd loss (%)

among

uncorrected corrected

#1 0.42 12.1 67.6

#1 1.04 29.3 69.9

#2 1.96 1.3 50.9

#2 4.11 3.4 50.5

no I-SceIH2-Kd stained

+ I-SceIstained H2-Kd

+ I-SceIunstained

Correction @ A Mutation @ B

Page 8: Optimizing  efficiency and safety of targeted gene correction

100 101 102 103 104

100

101

102

103

104

100 101 102 103 104

100

101

102

103

104

100 101 102 103 104

100

101

102

103

104

9.7% 10.9%

0.77% 0.67%

1.62%

89.4% 86.6%

1.96%

1.34% 0%

0.001%

H2-Kd (PE)

GFP

Cell line Targeting (%) H2-Kd loss (%)

among

uncorrected corrected

#1 0.42 12.1 67.6

#1 1.04 29.3 69.9

#2 1.96 1.3 50.9

#2 4.11 3.4 50.5

no I-SceIH2-Kd stained

+ I-SceIstained H2-Kd

+ I-SceIunstained

Correction @ A Mutation @ B